Loading patent…
AssigneeKymab Limited
InventorsMartina RAUNER, Lorenz HOFBAUER, Uwe PLATZBECKER, Ulrike BASCHANT, Igor THEURL, Volker GERMASCHEWSKI
Estimating the term…
The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases. The invention also relates to a transferrin receptor 2 inhibitor for use in the treatment of bone diseases, iron metabolism disorders or hematopoietic disorders.
A method of treating or preventing a bone disease or condition in a human or non-human mammalian subject, the method comprising administering a transferrin receptor 2 (Tfr2) antagonist to the subject and antagonizing Tfr2 in the subject.
A pharmaceutical composition comprising a Tfr2 antagonist and a pharmaceutically acceptable diluent, excipient, or carrier.
A method of treating or preventing a disease or condition mediated by a Bone Morphogenetic Protein (BMP) in a human or animal subject, the method comprising administering a BMP-binding agent to the subject, wherein the agent competes with soluble Tfr2 extracellular domain (Tfr2-ECD) for binding to the BMP.
A method of treating or preventing a bone disease or condition in a human or non-human mammalian subject, the method comprising administering a transferrin receptor 2 (Tfr2) agonist to the subject and agonizing Tfr2 in the subject.
A pharmaceutical composition comprising a Tfr2 agonist and a pharmaceutically acceptable diluent, excipient, or carrier.
Dependencies are inferred from the claim text.